|
|
|
| Effect and mechanism discussion of Berberine combined with quadruple therapy in the treatment of Helicobacter pylori-positive peptic ulcer |
| SHI Peng YAO Jie▲ |
| Department of Gastroenterology, the Sixth People′s Hospital of Chongqing City, Chongqing 400060, China |
|
|
|
Abstract Objective To investigate the effect and possible mechanisms of Berberine combined with quadruple therapy in the treatment of Helicobacter pylori (Hp)-positive peptic ulcer. Methods Forty cases of Hp-positive peptic ulcer patients in the Sixth People′s Hospital of Chongqing City from December 2015 to February 2018 were collected and divided into combined group and control group by using random number table method, each group of 20 cases. Control group was treated with quadruple therapy, while combined group was treated with Berberine on the basis of quadruple therapy. The curative effect, eradication rate of Hp and adverse reactions of two groups were observed. The expression of COX-2 in gastric tissues of two groups before and after treatment was compared. Results There was no significant difference in total effective rate between two groups (P > 0.05). The eradication rate of Hp in combined group was higher than that in control group (P < 0.05). There was no significant difference in incidence of abdominal pain, abdominal distension, nausea, diarrhea and taste changes between two groups (P > 0.05). After treatment, the expression of COX-2 in gastric tissue of both groups was lower than those before treatment, and the expression of COX-2 in gastric tissues of combined group was lower than that of control group (P < 0.05). Conclusion Berberine combined with quadruple therapy is superior to quadruple therapy alone in the treatment of Hp-positive peptic ulcer. Berberine may promote ulcer healing and Hp eradication by inhibiting the expression of COX-2.
|
|
|
|
|
|
[1] 黄雷，陈宁，余祝.黄连素联合三联疗法治疗幽门螺旋杆菌阳性的消化性溃疡的临床疗效观察[J].现代实用医学，2017，29（5）：591-593.
[2] Ishaq S，Nunn L. Helicobacter pylori and gastric cancer：a state of the art review [J]. Gastroenterol Hepatol Bed Bench，2015，8：S6-S14.
[3] 欧阳艳君，张艳梅，李炳东，等.雷贝拉唑三联疗法对活动期胃溃疡患者组织学愈合质量及溃疡复发的作用分析[J].现代中西医结合杂志，2014，23（20）：2196-2198.
[4] 王国庄.胃溃疡应用阿莫西林与泮托拉唑联合治疗的临床分析[J].中国医药指南，2014，12（19）：207-208.
[5] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组，刘文忠，谢勇，等.第四次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志，2012，32（10）：655-661.
[6] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组，刘文忠，谢勇，等.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志，2012，51（10）：832-837.
[7] Majumder M，Xin X，Liu L，et al. COX-2 induces breast cancer stem cells via EP4/PI3K/Akt/Notch/Wnt axis [J]. Stem Cells，2016，34（9）：2290-2305.
[8] Tseng YC，Tsai YH，Tseng MJ，et al. Notch2-induced COX-2 expression enhancing gastric cancer progression [J]. Mol Carcinog，2012，51（12）：939-951.
[9] 杨艳琼.消化内镜联合四联疗法治疗胃溃疡出血的疗效和再出血因素分析[J].世界临床医学，2016，10（20）：60-61.
[10] 罗玉琴，吴开春，孙安华，等.浅表性胃炎、胃黏膜不典型增生及胃癌组织中COX-1、COX-2、iNOS表达的意义[J].中华消化杂志，2000，20（4）：223-226.
[11] 阴俊，江梅.泮托拉唑治疗胃溃疡42例临床疗效观察[J].陕西医学杂志，2014，43（3）：378-379.
[12] 龙耀.奥美拉唑泮托拉唑和雷贝拉唑治疗胃溃疡的疗效及副反应比较[J].基层医学论坛，2013，17（35）：4716-4717.
[13] 张晓丹.三联疗法联合中药对胃溃疡患者血清炎症因子的影响[J].中国医药科学，2017，7（2）：53-55，63.
[14] 谭明琴.温胃汤联合奥美拉唑、阿莫西林、克拉霉素治疗Hp阳性胃溃疡的疗效[J].中国现代医生，2017，55（29）：119-121.
[15] 郑冬梅.奥美拉唑、泮托拉唑、兰索拉唑治疗胃溃疡疗效比较[J].现代中西医结合杂志，2014，23（22）：2461-2463.
[16] 李娟，傅颖媛.IgY、黄连、太子参影响幽门螺杆菌感染小鼠胃黏膜的变化[J].中国临床康复，2006，10（31）：78-80.
[17] Yang P，Song DQ，Li YH，et al. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators [J]. Bioorg Med Chem Lett，2008，18（16）：4675-4677.
[18] 张丽，董鑫.消化内镜联合四联疗法治疗胃溃疡出血的临床疗效及再出血影响的因素[J].河北医学，2017，23（7）：1180-1183.
[19] 王燕凌，苗智慧，牛丽静，等.不同剂量黄连素对心肌缺血大鼠的抗氧化损伤作用[J].河北中医，2010，32（2）：267-269.
[20] 李海东，秦刚，徐苏洋，等.黄连及其活性成分对缺血-再灌注损伤保护机制[J].国际骨科学杂志，2011，32（5）：321-323.
[21] 姚希贤，姚冬梅.中药联合“三联疗法”治疗幽门螺杆菌感染[J].现代消化及介入治疗，2010，15（2）：104-107.
[22] 黄常勇，李曙晖.黄连素联合三联疗法治疗幽门螺杆菌阳性消化溃疡的临床疗效[J].中国临床实用医学，2016， 7（3）：10-11. |
|
|
|
